Last week's vaccine advisory committee meeting revealed several Respiratory Syncytial Virus (RSV) products might become available later in 2023.
These products are essential since RSV can be severe, especially for infants. RSV is the most common cause of bronchiolitis and pneumonia in young children in the United States.
Read More
